biostudies-literatureCui ZNational Key Clinical Specialty Discipline Construction Program of ChinaNational Key Research and Development Program of China363https://www.ebi.ac.uk/biostudies/studies/S-EPMC11272681biostudies-literatureUnknown150(7)<h4>Purpose</h4>IKAROS family zinc finger 3 (IKZF3) is an oncogene involved in different malignancies, particularly in the development and malignant progression of lymphocytes. However, IKZF3 amplification and clinical significance in gastric cancers (GCs) remain unexplored.<h4>Methods</h4>We examined IKZF3 amplification status in 404 GCs with HER2 amplification status using tissue microarray (TMA) and fluorescence in situ hybridization (FISH) assays.<h4>Results</h4>IKZF3 amplification was detected in 6.9% (28/404) of all GC patients, with higher rates in intestinal-type gastric cancer (IGC) (11.22%, 22/196) compared to other types (2.88%, 6/208). HER2 amplification was identified in 16.09% (65/404) of all GC patients, with higher rates in IGC (20.92%, 41/196) compared to other types (11.5Journal of cancer research and clinical oncologyIKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer.PMC11272681YWP2023-0012021YFF1201001Liang HHuang JHuang WCui ZXu CZhang LSu JLuan LLuo RYuan WHou YfalseIKZF3 amplification predicts worse prognosis especially in intestinal-type gastric cancer.<h4>Purpose</h4>IKAROS family zinc finger 3 (IKZF3) is an oncogene involved in different malignancies, particularly in the development and malignant progression of lymphocytes. However, IKZF3 amplification and clinical significance in gastric cancers (GCs) remain unexplored.<h4>Methods</h4>We examined IKZF3 amplification status in 404 GCs with HER2 amplification status using tissue microarray (TMA) and fluorescence in situ hybridization (FISH) assays.<h4>Results</h4>IKZF3 amplification was detected in 6.9% (28/404) of all GC patients, with higher rates in intestinal-type gastric cancer (IGC) (11.22%, 22/196) compared to other types (2.88%, 6/208). HER2 amplification was identified in 16.09% (65/404) of all GC patients, with higher rates in IGC (20.92%, 41/196) compared to other types (11.52024-01-01T00:00:00Z2024 Jul2026-03-31T11:02:03.999Z2025-04-06T19:29:11.694ZS-EPMC112726813905210810.1007/s00432-024-05868-2